IRX1在宫颈癌中的表达及其与癌症分期的相关性  

Expression of IRX1 in cervical cancer and its correlation with clinical stage of cervical cancer

作　　者：何杨[1] 黄奕[1] 李娜 严浩[1] 杨润峰[1] 蒋蕾[1] 蒋孝会 曹波[1] 

机构地区：[1]湖北省肿瘤医院妇瘤科,武汉430079 [2]华中科技大学同济医学院附属同济医院

出　　处：《中华医学杂志》2018年第3期222-226,共5页National Medical Journal of China

基　　金：国家自然科学基金青年科学基金（81402164）

摘　　要：目的研究IRXl（易洛魁家族同源盒基因，Iroquoishomeoboxgene）在宫颈癌中的表达及其与症癌分期的相关性。方法选取2015年1月至2017年1月期间来湖北省肿瘤医院就诊的61例宫颈癌患者作为研究对象，其中国际妇、产科联合会I期15例，Ⅱ期22例，Ⅲ期19例，Ⅳ期5例。以正常的人子宫颈上皮细胞HCerEpiC为对照，采用免疫印迹检测IRXl在宫颈癌细胞株Hela，C4—1，Siha中IRXl的蛋白表达，收集宫颈癌癌变组织为实验样本，qPCR检测不同分期宫颈癌癌变组织中IRXlmRNA表达水平，免疫组化检测IRXl在宫颈癌组织中的表达以及其与临床分期的相关性。结果免疫印迹检测结果表明，IRXl在各宫颈癌细胞株中的表达高于正常的宫颈上皮细胞，且qPCR检测结果也表明在基因水平上IRXl的表达随癌症分期增加而增加，免疫组化结果显示，IRXl在胞核及胞质中都有表达，癌症分期越高其阳性表达量也相应增高，I期阳性着色率为0，1I期为64％，DI期为84％，1V期为100％。结论IRXl的表达与宫颈癌的临床分期相关，这表明IRXl可能参与了宫颈癌的发生与发展，IRXl有望成为临床上宫颈癌诊断与治疗的新的分子靶点，为宫颈癌的治疗提供新的理论依据。Objective To study the expression of IRX1 （Iroquois homeobox gene） in cervical cancer and its correlation with clinical stage of cervical cancer. Methods A total of 61 patients with cervical cancer from January 2015 to January 2017 were enrolled in this study, of which 15 were classified as phase I of cervical cancer, 22 patients were classified as phase ]I , 19 cases were classified as phase m, 5 cases were classified as phase IV foUowed FIGO staging criteria. The expression of IRX1 protein in Hela, C4-1 and Siha cell lines were detected by Western blot compared with the normal human cervical epithelial cells HCerEpiC. Collected cancerous tissue of cervical cancer as experimental samples, the expression of IRX1 mRNA in cancer tissues and paracancerous tissue were detected by qPCR. Immunohistochemistry was used to detect the expression of IRX1 in different stages of cervical cancer,the correlation between IRX1 expression and clinical stage was analyzed. Results The results of Western blot showed that IRX1 expression in cervical cancer cells were higher than that in normal cervical epithelial cells, and the results of qPCR also showed that the expression of IRX1 increased with the stage of cancer at the gene level. The difference was statistically significant. The expression of IRX1 in the nucleus and cytoplasm were detected by immunohistochemistry. Immunohistochemical results showed that the higher the stage of cancer was, the higher the expression rate of IRX1 was. Conclusion IRXI expression is associated with the clinical stage of cervical cancer, suggesting that IRX1 may be involved in the development and progression of cervical cancer. IRX1 is expected to be a new molecular target for the diagnosis and treatment of cervical cancer. This study will provide a new theoretical basis for the treatment of cervical cancer.

关 键 词：宫颈癌 IRX1 临床分期 

分 类 号：R737.33[医药卫生—肿瘤]